Christine Rollier

Add links
From Wikipedia, the free encyclopedia

Christine Rollier
Born
France
Alma materUniversity of Lyon
Scientific career
InstitutionsOxford Vaccine Group
Jenner Institute
University of Oxford
University of Surrey
ThesisEtude, à l'aide du virus de l'hépatite B du canard, de l'immunisation génétique pour la prévention et le traitement de l'hépatite B (2000)

Christine Rollier is a French immunologist who is a professor at the University of Surrey. She focusses on the development of vaccines to treat infectious diseases. In particular, Rollier has focussed on the development of vaccinations to eliminate the plague.

Early life and education[edit]

Rollier was born in France.[1][2] She was an undergraduate student in biochemistry at the University of Lyon.[1][3] Her doctoral research considered DNA immunisation as a therapeutic tool to treat people with Hepatitis B. She worked alongside physicians at the Inserm (Institut National de la Sante et Recherche Medicale). After earning her doctorate, Rollier moved to the Biomedical Primate Research Center in The Netherlands,[2] where she worked for six years on the development of vaccines against Hepatitis C.[3]

Research and career[edit]

Rollier joined the Jenner Institute in 2007, where she worked as a senior immunologist to improve viral vectored based vaccines. Her first position at Oxford was in the laboratory of Adrian Hill. In 2010, she joined the Oxford Vaccine Group.[4] She was interested in the design of viral vector vaccines specifically for bacterial diseases. Rollier focussed on bacterial and infectious diseases that affect children such as group B meningococcus and whooping cough. She has also focussed on vaccine candidates to fight the plague, typhoid and paratyphoid fever.[5]

In the early days of the COVID-19 pandemic, Rollier shifted her focus to support the Oxford's work on developing a COVID-19 vaccine.[1] She worked on a vaccine against the plague, which made use of the ChAdOx1 vaccine vector.[6][7][8] Outbreaks of the plague continue to occur around the world, impacting communities across rural Africa and the United States.[6][9] The disease is endemic in Madagascar, with outbreaks in 2017 and 2021.[10] ChAdOx1 is a weakened version of chimpanzee adenoviridae (the common cold virus).[6] Specifically, Rollier and co-workers added genes to generate proteins from Yersinia pestis, the plague bacterium.[6][11] These proteins are important in the plague bacterium infection pathway, and teach the body to recognise and fight against plague bacteria.[6] Rollier has said it is challenging to develop vaccinations against the plague as this is a disease affecting underprivileged populations.[10]

In 2021, Rollier moved to the University of Surrey, where she was made Professor of Vaccinology.[12]

Selected publications[edit]

  • Christine S Rollier; Arturo Reyes-Sandoval; Matthew G Cottingham; Katie Ewer; Adrian V S Hill (20 April 2011). "Viral vectors as vaccine platforms: deployment in sight". Current Opinion in Immunology. 23 (3): 377–382. doi:10.1016/J.COI.2011.03.006. ISSN 0952-7915. PMID 21514130. Wikidata Q37868123.
  • Christine S Rollier; Glaucia Paranhos-Baccala; Ernst J Verschoor; et al. (1 March 2007). "Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity". Hepatology. 45 (3): 602–613. doi:10.1002/HEP.21573. ISSN 0270-9139. PMID 17326154. Wikidata Q43036305.
  • Katie J. Ewer; Teresa Lambe; Christine S Rollier; Alexandra Spencer; Adrian V. S. Hill; Lucy Dorrell (August 2016). "Viral vectors as vaccine platforms: from immunogenicity to impact". Current Opinion in Immunology. 41: 47–54. doi:10.1016/J.COI.2016.05.014. ISSN 0952-7915. PMID 27286566. Wikidata Q24574798.

Personal life[edit]

Rollier has two children, and took an eighteen-month career break after having her first child.[2]

References[edit]

  1. ^ a b c "5 questions to Professor Christine Rollier, researcher at the Oxford Vaccine Group". France in the United Kingdom - La France au Royaume-Uni. Retrieved 26 December 2021.
  2. ^ a b c "Dr Christine Rollier — Working for NDM". www.ndm.ox.ac.uk. Retrieved 26 December 2021.
  3. ^ a b "Christine S. Rollier". www.jenner.ac.uk. Retrieved 26 December 2021.
  4. ^ "Christine S. Rollier". www.medsci.ox.ac.uk. Retrieved 26 December 2021.
  5. ^ "Dr Christine S Rollier". University of Birmingham. Retrieved 26 December 2021.
  6. ^ a b c d e "Phase 1 Trial Begins for Oxford University's ChAdOx1 Plague Vaccine". Global Biodefense. 26 July 2021. Retrieved 26 December 2021.
  7. ^ "Oxford Scientists Are Testing a Vaccine for the Plague". Gizmodo. Retrieved 26 December 2021.
  8. ^ "Plague Vaccine Being Trialed By Team Behind One Of The First Successful COVID Vaccines". IFLScience. Retrieved 26 December 2021.
  9. ^ "What was the Black Death and how did it end?". The Week UK. Retrieved 26 December 2021.
  10. ^ a b Brown, Will; Rigby, Jennifer (13 September 2021). "Plague hits Madagascar as Oxford team races to finish the revolutionary vaccine". The Telegraph. ISSN 0307-1235. Retrieved 26 December 2021.
  11. ^ "Phase I trial begins of new vaccine against the Plague | University of Oxford". www.ox.ac.uk. Retrieved 26 December 2021.
  12. ^ "Prof Christine Rollier | University of Surrey". www.surrey.ac.uk. Retrieved 26 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Christine_Rollier&oldid=1219532429"